TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01396135
Drug: CP-601,927
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1 mg CP-601,927 given as oral 1 mg tablets
Study: NCT01396135
Drug: CP-601,927
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of CP-601,927 given as 2 mg BID (4 mg/day) as oral 1 mg tablets for 7 days
Study: NCT01396135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of placebo given as a matching number of oral tablets
Study: NCT00777296
Drug: ARIKACE™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study start date is before Jan 18, 2017.
Study: NCT00777296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study start date is before Jan 18, 2017.
Study: NCT02569970
Drug: fluoxetine 20 mg
Normalized name: fluoxetine 20 MG
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label.
Study: NCT02569970
Drug: placebo 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label.
Study: NCT00092118
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one placebo tablet, taken once daily at bed time for 6 weeks
Study: NCT01631539
Drug: 5 FU
Normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 2 weeks IV
Study: NCT01464593
Drug: Lyso-Thermosensitive Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermally sensitive liposomal doxorubicin 50 mg/m2 single 30 minute intravenous infusion.
Study: NCT01464593
Drug: ThermoDox
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThermoDox is a Lyso-thermosensitive Liposomal Doxorubicin designed to be used in conjunction with thermal ablation.
Study: NCT03569930
Drug: flavonoid-based supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingredients: soybean oil (glycine max), edible gelatin, rutin, borage seed oil (borago officinalis), pineapple dry extract (ananas sativus), glycerol, thickeners (mono and diglycerides of fatty acids), emulsifier (soy lecithin).
Study: NCT00672724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon placebo-matching tablets, taken orally, once daily for up to 2 weeks.
Study: NCT02888041
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
Study: NCT01908075
Drug: FP/SAL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01908075
Drug: BDP/FOR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01288937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly assigned to placebo for 9 weeks (including a 1 week dose titration period), matching the schedule of the study drug.
Study: NCT00879905
Drug: HSP990
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00775229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: pill, by mouth, daily
Study: NCT00386360
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral weekly for one year
Study: NCT03458481
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg tablet administered orally once daily
Study: NCT03458481
Drug: DAG181
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule administered orally once daily
Study: NCT02647190
Drug: Erwinia Chrysanthemi asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01419392
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, 4 times per day for 21 days
Study: NCT05623540
Drug: Bisphosphonates, Combinations
Normalized name: Bisphosphonates, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00616148
Drug: YKP3089
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosage form
Study: NCT00616148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03390972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl 0.9%) TCI infusion
Study: NCT01560234
Drug: AZD8848
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, oral inhalation (nebuliser solution)
Study: NCT01560234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, oral inhalation (nebuliser solution)
Study: NCT00264719
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 10 mg
Study: NCT02069041
Drug: FOLFOX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT00080756
Drug: therapeutic testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.275mg/100ul per day as a nasal spray
Study: NCT00439283
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06181188
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients randomized to the midazolam and fentanyl arm will receive 25mcg incremental doses for procedural sedation
Study: NCT01006122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving placebo will undergo the same procedures as those receiving active treatment. Each patient will receive matching placebo tablets in a fixed dose escalation schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at 1.0 mg; decrease to 0.5 mg or increase to 2.0 mg based upon the clinicians judgment regarding efficacy and side effects at the 1.0 dose level. The patient will then remain at the determined dose for a 3 week stable dosing period, with a 7 (-2/+ 9) day wash out and then crossover to repeat the same sequence for the second arm of the study.
Study: NCT01431716
Drug: EFI/ACT-385781A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002943
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03493854
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 600 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of ddAC Q2W or AC Q3W) for Cycles 1-4.
Study: NCT03493854
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of either ddAC Q2W or AC Q3W) for Cycles 1-4.
Study: NCT03493854
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
Study: NCT00328497
Drug: Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panzem NCD 1,000 mg, four times daily for 28 consecutive days bevacizumab 5 mg/kg intravenous bolus on Day 1 and Day 15
Study: NCT02094352
Drug: Control Group + Epidural infusion
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The saline and epidural infusions will be administered over 96 hours with appropriate titration.
Study: NCT02094352
Drug: Control Group Booster Infusion
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive three saline booster infusions over the course of three months.
Study: NCT03517566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily from baseline until week 16
Study: NCT03517566
Drug: ZPL389 3mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZPL389 3 mg oral powder; once daily from baseline to week 16
Study: NCT03517566
Drug: ZPL389 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZPL389 10 mg oral powder; once daily from baseline to week 16
Study: NCT02239731
Drug: FDX104 (4% Doxycycline)
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks
Study: NCT03517566
Drug: ZPL389 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZPL389 30 mg oral powder; once daily from baseline to week 16
Study: NCT03517566
Drug: ZPL389 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZPL389 50 mg oral powder; once daily from baseline to week 16
Study: NCT03086330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide placebo, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
Study: NCT01757535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically matching placebo tablets on days 1 to 14 of each 28-day treatment cycle.
Study: NCT02449031
Drug: TOBI® PODHALER®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02449031
Drug: TOBI®
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: tobramycin inhalation solution, USP
Study: NCT02449031
Drug: Bethkis®
Approvals — FDA: no, EMA: no, PMDA: no
Description: tobramycin inhalation solution
Study: NCT02449031
Drug: Cayston®
Approvals — FDA: no, EMA: no, PMDA: no
Description: aztreonam for inhalation solution
Study: NCT00403481
Drug: Olmesartan medoxomil plus Hydrochlorothiazide
Normalized name: hydrochlorothiazide / olmesartan medoxomil Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan medoxomil and hydrochlorothiazide combination tablets, once daily, if necessary
Study: NCT02929589
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days
Study: NCT02929589
Drug: Opioid Medication
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
Study: NCT02929589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain
Study: NCT02929589
Drug: Ibuprofen + Opioid medication
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days. 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
Study: NCT06041451
Drug: Intravenous Immunoglobulins, Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients were treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days
Study: NCT02332057
Drug: Diclofenac plus lidocaine
Normalized name: diclofenac / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study nurse will instruct the patients to swallow diclofenac tablets (100 mg) 1 hour before IUD insertion. Three millilitres of the lidocaine gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the lidocaine gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
Study: NCT00335218
Drug: Climodien / Lafamme (BAY86-5027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet daily (2 mg EV + 2 mg DNG)
Study: NCT02332057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study nurse will instruct the patients to swallow placebo tablets 1 hour before IUD insertion. Three millilitres of the placebo gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the placebo gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
Study: NCT02684097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo given every two weeks for 24 weeks
Study: NCT03507634
Drug: Opioid based anesthesia Fentanyl and Remifentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Opioid based anesthesia with Fentanyl and Remifentanyl
Study: NCT02264626
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: infusion at a rate by 0.025 μg kg-1 min-1 every minute to a maximum of 0.15 μg kg-1 min-1.
Study: NCT00335218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet daily
Study: NCT00396071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT04090229
Drug: ASLAN004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of ASLAN004 100 mg/mL will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
Study: NCT04090229
Drug: ASLAN004 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of ASLAN004 Placebo will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
Study: NCT03689829
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corresponding placebo s.c. injections.
Study: NCT02887183
Drug: LCZ696 (sacubitril/valsartan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 (sacubitril/valsartan) was supplied as unscored, ovaloid, film-coated oral tablets in the strengths of 24/26 mg, 49/51 mg, 97/103 mg to be taken twice daily (bid)
Study: NCT04181476
Drug: Sunscreening Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four different sunscreens
Study: NCT03313557
Drug: Wee-1 kinase inhibitor AZD1775
Normalized name: PROTEIN KINASE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive AZD1775 300 mg orally once daily. Days 1 to 5 and 8 to 12 of a 21 day cycle (ie, 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle). All patients must receive a serotonin receptor 3 (5-HT3) antagonist, ondansetron (Zofran) 8 mg orally/IV or granisetron (Kytril) 1 mg orally/IV prior to each dose of AZD1775. Dexamethasone 4 mg orally/IV will be given with each AZD1775 dose at a minimum on the first day of dosing of AZD1775 of every 5 day dosing period, unless contraindicated or not well-tolerated.
Study: NCT03955705
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium chloride (normal saline or NSS)
Study: NCT00810667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily oral dose
Study: NCT04168112
Drug: Prednisolone Acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: post-crosslinking eye drop prednisolone acetate given in a tapering schedule over 1 month
Study: NCT03768908
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three day treatment with Artemether-lumefantrine, 2 doses a day under direct observation
Study: NCT02505750
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00636246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, orally once per day for 8 weeks
Study: NCT03091543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules of placebo
Study: NCT03091543
Drug: BIA 6-512 25 mg dose
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule of 25 mg plus 1 capsule of placebo
Study: NCT03091543
Drug: BIA 6-512 50 mg dose
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules of 25 mg
Study: NCT03091543
Drug: BIA 6-512 100 mg dose
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule of 100 mg plus 1 capsule of placebo
Study: NCT03091543
Drug: BIA 6-512 200 mg dose
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules of 100 mg
Study: NCT00839683
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 20 mg, Single Dose
Study: NCT00839683
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, 40 mg, Single Dose
Study: NCT01997788
Drug: The intravenous patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intravenous injection of morphine using the patient-controlled analgesia machine
Study: NCT01997788
Drug: Demerol on demand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demerol 25 mg intravenously when pain scores more than 5.
Study: NCT02127840
Drug: Synacthen infusion during adrenal venous sampling
Normalized name: adrenal cortex extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenal venous sampling during Synacthen infusion
Study: NCT02499367
Drug: Low dose doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg flat dose, once weekly for 2 weeks
Study: NCT02499367
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: metronomic schedule, 50 mg daily orally for 2 weeks
Study: NCT00687271
Drug: MK-6213
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-6213 160 mg for 4 weeks.
Study: NCT00687271
Drug: Placebo for MK-6312 160 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02652468
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV for 2 days
Study: NCT02323373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of saline solution administered with anesthesia during 10 minutes
Study: NCT01966120
Drug: Placebo to BF-200 ALA gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The reference product was a placebo (a nanoemulsion gel formulation similar to the Investigational Medicinal Product (IMP), but without the active ingredient). The placebo was packaged, assigned to each patient, and administered in the same way as the IMP.
Study: NCT04116840
Drug: MT1002 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug will be administered by an intravenous bolus dose followed by an infusion of 4 hours.
Study: NCT00461630
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg simvastatin tablet orally per day as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
Study: NCT04608396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken daily for up to 52 weeks, until relapse.
Study: NCT01058642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00442897
Drug: simvastatin (+) ezetimibe
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks)
Study: NCT04498182
Drug: AR-15512 Ophthalmic Solution Vehicle
Normalized name: OPTI VET AR 0.025 % / 0.3 % Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic solution vehicle administered via topical ocular instillation
Study: NCT01704495
Drug: AZD5069
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5069 oral capsules self-administered twice daily.
Study: NCT01704495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsules self-administered twice daily.
Study: NCT03174535
Drug: Qilong capsules (QLC), produced by Jining Huaneng Pharmaceutical Factory Co., Ltd.
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks.
Study: NCT02367118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00390871
Drug: Fentanyl/Dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00390871
Drug: Fentanyl/Propofol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00390871
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00256412
Drug: Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and Omega 3 capsules. All participants receive 4 capsules with either 0, 2, or 4 capsules containing omega 3.
Study: NCT00256412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules of placebo each day
Study: NCT03188289
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is the control group treated with a placebo gel.
Study: NCT02588612
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Study: NCT01676441
Drug: cellgram-spine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cells transplantation
Study: NCT01268943
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.